Mesoblast (NASDAQ:MESO) Trading Up 3.4% – Still a Buy?

Shares of Mesoblast Limited (NASDAQ:MESO) traded up 3.4% during trading on Tuesday . The company traded as high as $11.40 and last traded at $11.40. 454 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 750,209 shares. The stock had previously closed at $11.03.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MESO shares. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Tuesday, September 24th. StockNews.com cut Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Jefferies Financial Group upgraded Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday, August 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Mesoblast Stock Performance

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The business’s 50-day moving average is $9.16 and its 200 day moving average is $7.75.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Perkins Coie Trust Co boosted its stake in shares of Mesoblast by 15.0% in the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after buying an additional 1,500 shares during the period. GAMMA Investing LLC lifted its position in shares of Mesoblast by 50.1% during the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after acquiring an additional 1,663 shares during the period. Signaturefd LLC grew its holdings in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares in the last quarter. Lazari Capital Management Inc. increased its position in shares of Mesoblast by 6.6% in the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after purchasing an additional 3,300 shares during the period. Finally, Chapin Davis Inc. raised its stake in Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after purchasing an additional 5,000 shares in the last quarter. 1.43% of the stock is owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.